Report Subject - Orphan Drugs - FirstWord Reports

Learn More Payer Attitudes to Orphan Drug Pricing

Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached...

Compare
Learn More Medical Affairs in Orphan Drugs

Orphan drugs: Is your medical affairs team leading the fray or lagging behind? Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...

Compare
Learn More Orphan Drugs: Pricing and Market Access Strategies

Orphan drug market access and pricing: strategies for success When it comes to securing market access and drug pricing for orphan drugs, a one size approach won’t work. Driven by increasing competition and cost...

Compare
Learn More Orphan Drug Market Access: Payer Insights on the Present and Future (2016)

How to ensure positive payer engagement for orphan drug market access The explosion in orphan drug approvals and high prices are causing increasing concern to payers. When there were few orphan drugs for small patient...

Compare
Learn More The Future of Orphan Drugs

Orphan Drugs: Future opportunities and challenges The orphan drug sector is booming. Record product approvals, robust pipelines and regulatory incentives. But will the good times last? As the market matures...

Compare
Learn More Orphan Drug Commercial Models: Sustaining the rare disease business

Choosing the right commercial model for orphan drug success The societal and commercial ambitions of orphan drug developers determine which commercial model will best meet their aims. Profit, potential and patient...

Compare
Learn More Patient Engagement in Orphan Drugs

Why is the patient voice critical to orphan drug success? Patient input is critical to an orphan drug’s success, but how and when should you engage and what trends and drivers are shaping their involvement?...

Compare
Learn More Commercial Excellence in Rare Diseases and Orphan Drugs

Developing therapies for orphan diseases is attracting much industry interest with the promise of profits. But what are the specific R&D, regulatory, stakeholder and market access issues you need to understand and...

Compare

Browse by